Cover Page

Cite item


Aim: to study correlation between concentration of pathological cytokines and erythropoietin in patients with chronic heart failure with anemic syndrome and also to prove importance of this communication for need of appointment erythropoietin excitants. Patients and methods: 94 patients with chronic heart failure of New York Heart Association (NYHA) class ІІІ–ІV a left ventricular ejection fraction of 40% or less with anemia w ere included in investigation (58 males, 36 females). Anemia was detected when hemoglobin (Hb) was less than 120 g/l in males and less than 110 g/l in females. 46 patients received traditional treatment of CHF (І group) and 48 patients were treated additionally with erythropoietin (EPO) (ІІ group). Percutaneous EPO 50 IU monthly to patients without iron deficiency for a period of 6 months. Echocardiography parameters, plasma NT and pro-BNP, cytokines, EPO, ferritin and 6-minute walking test were assessed at baseline and after treatment. Results: in patients with CHF and anemia in ІІ group erythropoietin treatment increased Hb levels by 22,4% (p IL 6 by 54,3% (p α by 48,3% (p increase of LVEF by 19,04% (p Conclusions: Correction of anemia in patients with chronic heart failure with percutaneous erythropoietin injections 50 IU monthly for 6 month period to improve erythropoietin deficit and cytokines aggression and associated anemia, symptoms and quality of life.

About the authors

K. Kh. Zahidova

Azerbaijan State Advance Training Institute for Doctors, Baku

Author for correspondence.

кандидат медицинских наук, доцент кафедры кардиологии Азербайджанского государственного института усовершенствования врачей им. А. Алиева
Адрес: АZ1012, Баку, Тбилисский пр-т, д. 3165, тел.: (+994) 12 4501451



  1. Stamos T.D., Silver M.A. Management of anaemia in heart failure. Curr. Opin. Cardiol. 2010; 25: 148–154.
  2. Silverberg D.S., Wexler D., Blum M., Tchebiner J.Z., Sheps D., Keren G., Schwartz D., Baruch R., Yachnin T., Shaked M., Schwartz I., Steinbruch S., Iaina A. The effect of correction of anemia in diabetic and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneus erythropoietin and intravenous iron. Nephrol. Dial. Transplant. 2003; 18: 141–146.
  3. Iversen P.O., Woldbaek P.R., Tonnessen T., Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002; 282 (1): 166–172.
  4. Bolger A.P., Doehner W., Sharma R., Coats A.J.S., Anker S. Anemia in chronic heart failure: the relationship to inflammatory cytokine expression and prognostic importance. Circulation. 2002; 106 (Suppl.): 570–571.
  5. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure:an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001; 103: 2055–2059.
  6. Ivengar S., Abraham W.T. Anemia in chronic heart failure: Can EPO reduce death? Cleveland Clin. J. Med. 2005; 72 (11): 1027–1032.
  7. Gorg J., Patal S., Wexler D. Sharabi,Y., Peleg E., Kamari Y., Grossman E., Sheps D., Keren G., Roth A. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormanal and inflammatory markers. Arch. Intern. Med. 2005; 165 (11): 1304–1349.
  8. Yankowska E.A., Rozentryt P., Witkowska A. et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur. Heart J. 2010; 31 (15): 1872–1876.
  9. Silverberg D.S., Wexler D., Blum M., Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal functional and reduce hospitalizations . Clin. Nephrol. 2003; 60 (1): 93–102.
  10. Silverberg D.S., Wexler D., Iaina A., Schwartz D. Correction of iron deficiency in the cardio renal syndrome. Int. J. Nephrol. 2011; 365: 301.
  11. Torre-Amione G., Bourge R., Colucci S.W., Greenberg B., Pratt C., Rouleau J.-L., Sestier F., Movie L., Geddes J., Nemet A., Young J.B. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. Canadian J. Cardiol. 2007; 23 (5): 369–376.
  12. Тепляков А.Т., Дибиров М.М., Болотская Л.А. Модулирующее влияние карведилола на активацию цитокинов и регресс сердечной недостаточности у больных с постинфарктной дисфункцией сердца. Кардиология. 2004; 9: 50–57.

Copyright (c) 2015 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies